

Seventh Meeting of the HB 21-1317 Scientific Review Council

June 21, 2022

Opening Remarks, Introductions and Welcome, Updates on Conflict of Interest

Christopher E. Urbina, MD, MPH
Chair, HB 21-1317 Scientific Review Council

Cannabis Research & Policy Project Team Members

Member	Sub-Team
Lisa Bero, PhD	Systematic Review
Ashley Brooks-Russell, PhD, MPH	Subject Area Expertise
Meghan Buran, MPH	Administration
Kelsey Phinney, MPH	Administration
Neeloo Soleimanpour, MPH	Administration
Rosa Lawrence, BA	Systematic Review
Louis Leslie, BA	Systematic Review
Tianjing Li, MD, PhD, MHS	Systematic Review
Christi Piper, MLIS	Systematic Review
Thanitsara Rittiphairoj, MD, MPH	Systematic Review
Jean-Pierre Oberste, BA	Systematic Review
Jonathan Samet, MD, MS	Administration
Greg Tung, PhD, MPH	Administration, Subject Area Expertise
Sam Wang, MD	Subject Area Expertise

Scientific Review Council Members

Member	Role on Council per HB 21-1317	Affiliation(s)
Chris Urbina, MD, MPH (Chair)	Preventive medicine specialist (or preventive medicine public health professional)	Pueblo Department of Public Health and Environment; Former Director of CDPHE
Gregory Kinney, PhD, MPH	Epidemiologist	Colorado School of Public Health
David Brumbaugh, MD, MSc	Physician familiar with the administration of medical marijuana pursuant to current state laws to those aged zero to seventeen	Children's Hospital Colorado; University of Colorado School of Medicine
Kennon Heard, MD	Medical Toxicologist	University of Colorado School of Medicine
Archana Shrestha, MD	Neurologist	University of Colorado School of Medicine
Erica Wymore, MD, MPH	Pediatrician	University of Colorado, School of Medicine
Paula Riggs, MD	Psychiatrist	University of Colorado, School of Medicine
Susan Calcaterra, MD, MPH	Internal medicine physician (or other specialist in adult medicine)	University of Colorado School of Medicine
Joseph Schacht, PhD	Licensed Substance Abuse Disorder Specialist	University of Colorado School of Medicine
Kent Hutchison, PhD	Neuropsychopharmacologist	University of Colorado School of Medicine
Lesley Brooks, MD	Medical professional (or public health professional) who specializes in racial and health disparities and systemic inequalities in health care and medicine	North Colorado Health Alliance; SummitStone Health Partners

Review of Agenda

Christopher E. Urbina, MD, MPH
Chair, HB 21-1317 Scientific Review Council

Scientific Review Council Meeting Agenda

10:00 am	Opening Remarks, Introductions and Welcome, Updates on Conflict of Interest	Chris Urbina
10:10 am	Review of Agenda and Meeting Minutes (06/15/22)	Chris Urbina
10:15 am	Update on Progress of Review	Tianjing Li & Chris Urbina
10:25 am	<p>Items for Discussion with SRC</p> <ul style="list-style-type: none"> • Review Concentration Phrasing in Report • Share Preliminary Recommendations • Future Research Agenda • Next Steps 	Jon Samet & Chris Urbina
11:50 am	Next Meeting on June June 29 th , Future SRC Meetings, Finalize Report and Letter, and Closing Remarks	Chris Urbina & Jon Samet

Review of Meeting Minutes and Response to SRC Recommendations

Christopher E. Urbina, MD, MPH
Chair, HB 21-1317 Scientific Review Council

Cannabis Research & Policy Project

[Our Team](#)

[Scientific Review Council](#)

[Resources](#)

[Events](#)

[Contact Us](#)



Researching and educating on cannabis and health

The CRPP team studies cannabis and health, provides policy recommendations, and educates the public.

Who we are

The Cannabis Research & Policy Project team is a group of researchers from the Colorado School of Public Health and the University of Colorado Anschutz Medical Campus.

Update on Progress of Review

Tianjing Li, MD, PhD, MHS
Associate Professor, School of Medicine

Christopher E. Urbina, MD, MPH
Chair, HB 21-1317 Scientific Review Council

Updates from Cannabis Research & Policy Project

- Data Extraction Progress

Items for Discussion with SRC of the Drafted Report

Christopher E. Urbina, MD, MPH
Chair, HB 21-1317 Scientific Review Council

Jonathan M. Samet, MD, MS
Dean, Colorado School of Public Health

Feedback on the Following:

- Review Concentration Phrasing in Report
- Share Preliminary Recommendations
- Future Research Agenda
- Next Steps

Review Concentration Phrasing in Report

- Following discussion with SRC, will not use term potency in referring to concentration.
- Will use concentration throughout and refer to products as “high concentration”
- Will provide explanation in text, making reference to SRC discussion

Next Steps

As this report is written, the ColoradoSPH team is moving towards completion of data extraction from the 489 studies with information on exposures and outcomes. With completion of data extraction during July 2022, next steps will utilize the evidence map to:

- Examine the exposure/outcome pairs and assess the availability of data relevant to the review's main questions;
- Determine if there is sufficient evidence to warrant focused systematic reviews that would address high-concentrated THC products.

Next Steps

A subsequent step in meeting the mandate of HB 1317 would be to carry out *focused systematic reviews* for exposure/outcome pairs with sufficiently robust data. For these reviews, protocols for carrying out a systematic review would be followed, including the specification of a study question and the preparation of a protocol, and then proceeding through the steps of a systematic review. Depending on the scope of the data and its characteristics, the data might be pooled via a *meta-analysis and dose-response relationships might be modeled*.

Recommendations

- The convening of a workshop in collaboration with relevant professional societies to address the need for standardization of exposure assessment and study reporting;
- The development of a strategic research agenda that will close the knowledge gap for critical uncertainties.

SRC Plans and Approach

Christopher E. Urbina, MD, MPH
Chair, HB 21-1317 Scientific Review Council

Jonathan M. Samet, MD, MS
Dean, Colorado School of Public Health

**Next Meeting:
June 29th**

Review of HB 1317 Expectations

Christopher E. Urbina, MD, MPH
Chair, HB 21-1317 Scientific Review Council

Charge to the Colorado School of Public Health

Tasks for the Colorado School of Public Health in HB 21-1317

- Conduct a systematic review of high-potency THC marijuana
- Establish a Scientific Review Council
- Produce a public education campaign

High-Potency THC Marijuana and Marijuana Concentrate Research

- Conduct a systematic review of high-potency THC marijuana:
 - Systematically curate and synthesize the evidence regarding possible physical and mental health effects
 - Identify needed research
 - Report on gaps identified by 1/31/2022 and what needed to address the gaps, including funding and timeline for new studies
- **Provide initial report by 7/1/2022**
- Potentially conduct additional research
- The research must be conducted independently without any predetermined outcomes or undue influence from any party

Systematic Scoping Review

What type of systematic review? Per House Bill 21-1317

- “...all available scientific evidence-based research regarding the possible physical and mental health effects of high-potency THC marijuana and marijuana concentrates regardless of the location of the research.”
- “The research must systematically curate and synthesize existing research, identify evidence gaps, and identify new research that is needed to better understand the health implications of high-potency THC marijuana products and the specific THC potency levels and amounts at which various health concerns arise.”

Research Questions for the Review

- Identify and describe studies that explore the relationship of high-potency cannabis products with beneficial and adverse health outcomes
- Identify and describe studies that report adverse effects of exposure to high-potency products (with no comparison group)